link to RWJMS home page

Welcome to The Cancer Institute of New Jersey

As one of the nation’s 40 National Cancer Institute-designated Comprehensive Cancer Centers and the only one in New Jersey, The Cancer Institute of New Jersey (CINJ) delivers advanced comprehensive care to adults and children, and conducts cutting-edge cancer research.  Our researchers and physicians transform discoveries into clinical practice and provide education and outreach regarding cancer prevention, detection and treatment. 

Through our Network of hospitals, the reach of CINJ is statewide providing the best cancer care and the most advanced treatment options through-out the state, quite literally bringing research to life across New Jersey, the nation and beyond.

NotepadRequest an Appointment                              

                  

You Tube Logo
facebook


Clinical Trials News


Breast Cancer Study Seeks Healthy Volunteers
Research currently underway at CINJ and CINJ-Hamilton, which may unlock the mysteries of why some women develop breast cancer at an earlier age than others, has been expanded to include more healthy volunteers than previously sought.  Investigators hope to shed light on these figures through an ongoing clinical trial whose goal is to identify genetic markers for the disease. By including larger numbers of healthy women in the study, the researchers hope to pinpoint genetic differences between women who develop breast cancer and those who do not.  Read More


Clinical Trial Focuses on New Immune Therapy in Combination with Standard Treatment for Common Form of Kidney Cancer             
Researchers at CINJ are evaluating whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient’s relative. The Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients with Renal Cell Carcinoma -- or SPECIAL -- trial is sponsored by the United States Food and Drug Administration, which also will monitor the study.  Read More


Scientists Expand Research on Riluzole in Melanoma Patients Following Positive Clinical Trial Results
Following evidence of tumor shrinkage in a recent clinical trial at CINJ, new research has just begun to further measure the effects of a drug commonly used for Lou Gehrig’s disease (ALS) in the treatment of melanoma. Melanoma cells often produce a protein called Grm1, which aids in the growth of the disease. Riluzole, which is approved by the United States Food and Drug Administration for the treatment of ALS (a disease that affects nerve cells in the brain and spinal cord), has been shown to block Grm1’s action. Read More


Find a Clinical Trial at CINJ

 

CINJ Network Portal Login

 

 

The Cancer Institute of New Jersey
A National Cancer Institute-designated
Comprehensive Cancer Center

 

195 Little Albany Street
New Brunswick, NJ 08903-2681
732-235-CINJ

 

 

 

 

The Information contained in this web site is not a substitute for medical consultation. A physician should always be consulted for any health problem or medical condition.